Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.64
EXAC's Cash-to-Debt is ranked lower than
73% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. EXAC: 0.64 )
Ranked among companies with meaningful Cash-to-Debt only.
EXAC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.19 Max: No Debt
Current: 0.64
Equity-to-Asset 0.82
EXAC's Equity-to-Asset is ranked higher than
80% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. EXAC: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
EXAC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.73 Max: 0.88
Current: 0.82
0.39
0.88
Debt-to-Equity 0.06
EXAC's Debt-to-Equity is ranked higher than
81% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. EXAC: 0.06 )
Ranked among companies with meaningful Debt-to-Equity only.
EXAC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.17 Max: 1.04
Current: 0.06
0.02
1.04
Debt-to-EBITDA 0.49
EXAC's Debt-to-EBITDA is ranked higher than
77% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. EXAC: 0.49 )
Ranked among companies with meaningful Debt-to-EBITDA only.
EXAC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.4  Med: 0.81 Max: 1.52
Current: 0.49
0.4
1.52
Interest Coverage 8.47
EXAC's Interest Coverage is ranked lower than
76% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. EXAC: 8.47 )
Ranked among companies with meaningful Interest Coverage only.
EXAC' s Interest Coverage Range Over the Past 10 Years
Min: 7.53  Med: 16.85 Max: 28.71
Current: 8.47
7.53
28.71
Piotroski F-Score: 4
Altman Z-Score: 7.18
Beneish M-Score: -2.98
WACC vs ROIC
4.86%
0.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 3.05
EXAC's Operating Margin % is ranked higher than
50% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. EXAC: 3.05 )
Ranked among companies with meaningful Operating Margin % only.
EXAC' s Operating Margin % Range Over the Past 10 Years
Min: 2.96  Med: 9.59 Max: 12.05
Current: 3.05
2.96
12.05
Net Margin % 0.30
EXAC's Net Margin % is ranked lower than
52% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. EXAC: 0.30 )
Ranked among companies with meaningful Net Margin % only.
EXAC' s Net Margin % Range Over the Past 10 Years
Min: 0.06  Med: 5.9 Max: 7.19
Current: 0.3
0.06
7.19
ROE % 0.33
EXAC's ROE % is ranked lower than
52% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. EXAC: 0.33 )
Ranked among companies with meaningful ROE % only.
EXAC' s ROE % Range Over the Past 10 Years
Min: 0.07  Med: 7.68 Max: 10.86
Current: 0.33
0.07
10.86
ROA % 0.26
EXAC's ROA % is ranked higher than
51% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. EXAC: 0.26 )
Ranked among companies with meaningful ROA % only.
EXAC' s ROA % Range Over the Past 10 Years
Min: 0.06  Med: 5.43 Max: 7.81
Current: 0.26
0.06
7.81
ROC (Joel Greenblatt) % 4.12
EXAC's ROC (Joel Greenblatt) % is ranked lower than
51% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. EXAC: 4.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EXAC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.87  Med: 12.67 Max: 17.82
Current: 4.12
3.87
17.82
3-Year Revenue Growth Rate 1.20
EXAC's 3-Year Revenue Growth Rate is ranked lower than
60% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. EXAC: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EXAC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 14.2 Max: 30.5
Current: 1.2
-1.1
30.5
3-Year EBITDA Growth Rate -14.50
EXAC's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. EXAC: -14.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EXAC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.5  Med: 12.1 Max: 38
Current: -14.5
-14.5
38
3-Year EPS without NRI Growth Rate -79.30
EXAC's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. EXAC: -79.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EXAC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -79.3  Med: 13.5 Max: 34.6
Current: -79.3
-79.3
34.6
GuruFocus has detected 3 Warning Signs with Exactech Inc EXAC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EXAC's 30-Y Financials

Financials (Next Earnings Date: 2017-10-30)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

EXAC Guru Trades in Q3 2016

Jim Simons 98,600 sh (+9.43%)
Jeremy Grantham 9,121 sh (unchged)
Mario Gabelli 658,109 sh (-1.13%)
Chuck Royce 226,428 sh (-29.75%)
» More
Q4 2016

EXAC Guru Trades in Q4 2016

Jim Simons 105,700 sh (+7.20%)
Chuck Royce 240,128 sh (+6.05%)
Mario Gabelli 654,635 sh (-0.53%)
Jeremy Grantham 8,821 sh (-3.29%)
» More
Q1 2017

EXAC Guru Trades in Q1 2017

Chuck Royce 290,889 sh (+21.14%)
Jim Simons 110,600 sh (+4.64%)
Jeremy Grantham 8,821 sh (unchged)
Mario Gabelli 653,767 sh (-0.13%)
» More
Q2 2017

EXAC Guru Trades in Q2 2017

Jim Simons 131,400 sh (+18.81%)
Jeremy Grantham 8,821 sh (unchged)
Chuck Royce 277,659 sh (-4.55%)
Mario Gabelli 619,567 sh (-5.23%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Reduce -5.23%0.01%$24.95 - $31.7 $ 41.8543%619,567
Mario Gabelli 2017-03-31 Reduce -0.13%$24.15 - $28.8 $ 41.8563%653,767
Mario Gabelli 2016-12-31 Reduce -0.53%$22.6 - $28.35 $ 41.8558%654,635
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:IVC, NAS:GNMK, NAS:TCMD, MIL:ELN, NAS:CUTR, NAS:ARAY, XKRX:043150, NAS:VRAY, HKSE:03600, HKSE:01358, XKRX:060280, NAS:AXGN, OHEL:DETEC, OSTO:XVIVO, SZSE:300562, SZSE:300314, XKRX:054950, LSE:MGP, NAS:RTIX, ROCO:8406 » details
Headquarter Location:USA
Exactech Inc develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.

Exactech Inc develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.

Guru Investment Theses on Exactech Inc

Meridian Funds Comments on Exact Sciences Corp - Mar 08, 2016

Exact Sciences Corp. (NASDAQ:EXAC) declined after an independent panel of health care experts excluded the company’s colon cancer-screening test from a list of recommended tests in the U.S. Instead, the panel defined the product as “alternative testing that may be useful in select clinical circumstances.” Marketed as Cologuard, the product is a non-invasive, FDA-approved colorectal cancer-screening test covered by Medicare. It has proven effective at detecting early-stage colon cancer as well as precancerous lesions. When detected early, colon cancer is highly curable. However, Cologuard’s exclusion from the panel’s list of recommended tests may make it more difficult to win favorable reimbursement from private insurers. We consequently liquidated our position in Exact Sciences and used proceeds from the sale to invest in other, more attractive investment opportunities.





From the Meridian Equity Income Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 1395.01
EXAC's PE Ratio is ranked lower than
99% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. EXAC: 1395.01 )
Ranked among companies with meaningful PE Ratio only.
EXAC' s PE Ratio Range Over the Past 10 Years
Min: 13.63  Med: 21.8 Max: 3080
Current: 1395.01
13.63
3080
Forward PE Ratio 22.08
EXAC's Forward PE Ratio is ranked higher than
64% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. EXAC: 22.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 1395.01
EXAC's PE Ratio without NRI is ranked lower than
99% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. EXAC: 1395.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
EXAC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.63  Med: 21.8 Max: 3080
Current: 1395.01
13.63
3080
PB Ratio 2.43
EXAC's PB Ratio is ranked higher than
70% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. EXAC: 2.43 )
Ranked among companies with meaningful PB Ratio only.
EXAC' s PB Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.55 Max: 3.48
Current: 2.43
1.06
3.48
PS Ratio 2.30
EXAC's PS Ratio is ranked higher than
68% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. EXAC: 2.30 )
Ranked among companies with meaningful PS Ratio only.
EXAC' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.25 Max: 2.59
Current: 2.3
0.85
2.59
Price-to-Free-Cash-Flow 165.41
EXAC's Price-to-Free-Cash-Flow is ranked lower than
94% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. EXAC: 165.41 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EXAC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.48  Med: 34.79 Max: 407.87
Current: 165.41
14.48
407.87
Price-to-Operating-Cash-Flow 17.15
EXAC's Price-to-Operating-Cash-Flow is ranked higher than
73% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. EXAC: 17.15 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EXAC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.93  Med: 11.25 Max: 43.32
Current: 17.15
5.93
43.32
EV-to-EBIT 70.42
EXAC's EV-to-EBIT is ranked lower than
87% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. EXAC: 70.42 )
Ranked among companies with meaningful EV-to-EBIT only.
EXAC' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 14.8 Max: 70.59
Current: 70.42
9.2
70.59
EV-to-EBITDA 21.31
EXAC's EV-to-EBITDA is ranked higher than
54% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. EXAC: 21.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXAC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 8.5 Max: 21.36
Current: 21.31
5.7
21.36
EV-to-Revenue 2.30
EXAC's EV-to-Revenue is ranked higher than
72% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. EXAC: 2.30 )
Ranked among companies with meaningful EV-to-Revenue only.
EXAC' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 1.4 Max: 2.8
Current: 2.3
1
2.8
Shiller PE Ratio 46.35
EXAC's Shiller PE Ratio is ranked higher than
65% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. EXAC: 46.35 )
Ranked among companies with meaningful Shiller PE Ratio only.
EXAC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.72  Med: 25.83 Max: 51.8
Current: 46.35
17.72
51.8
Current Ratio 4.11
EXAC's Current Ratio is ranked higher than
73% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. EXAC: 4.11 )
Ranked among companies with meaningful Current Ratio only.
EXAC' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.47 Max: 8.45
Current: 4.11
1.64
8.45
Quick Ratio 2.16
EXAC's Quick Ratio is ranked higher than
52% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. EXAC: 2.16 )
Ranked among companies with meaningful Quick Ratio only.
EXAC' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 2.07 Max: 5.4
Current: 2.16
0.47
5.4
Days Inventory 315.39
EXAC's Days Inventory is ranked lower than
86% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. EXAC: 315.39 )
Ranked among companies with meaningful Days Inventory only.
EXAC' s Days Inventory Range Over the Past 10 Years
Min: 310.86  Med: 346.51 Max: 357.51
Current: 315.39
310.86
357.51
Days Sales Outstanding 80.14
EXAC's Days Sales Outstanding is ranked lower than
63% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. EXAC: 80.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.9  Med: 75.72 Max: 91
Current: 80.14
67.9
91
Days Payable 74.53
EXAC's Days Payable is ranked higher than
60% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. EXAC: 74.53 )
Ranked among companies with meaningful Days Payable only.
EXAC' s Days Payable Range Over the Past 10 Years
Min: 52.26  Med: 78.53 Max: 90.48
Current: 74.53
52.26
90.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
EXAC's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. EXAC: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.3  Med: -1.8 Max: -1
Current: -2
-18.3
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.87
EXAC's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. EXAC: 6.87 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXAC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.87  Med: 4.64 Max: 18.45
Current: 6.87
1.87
18.45
Price-to-Tangible-Book 2.70
EXAC's Price-to-Tangible-Book is ranked higher than
74% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. EXAC: 2.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXAC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 2.06 Max: 4.7
Current: 2.7
1.26
4.7
Price-to-Intrinsic-Value-Projected-FCF 2.50
EXAC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. EXAC: 2.50 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EXAC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.33  Med: 3.04 Max: 383
Current: 2.5
1.33
383
Price-to-Median-PS-Value 1.84
EXAC's Price-to-Median-PS-Value is ranked lower than
74% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. EXAC: 1.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXAC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.29 Max: 2.61
Current: 1.84
0.72
2.61
Price-to-Graham-Number 12.92
EXAC's Price-to-Graham-Number is ranked lower than
94% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. EXAC: 12.92 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EXAC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.89  Med: 1.44 Max: 13.7
Current: 12.92
0.89
13.7
Earnings Yield (Greenblatt) % 1.41
EXAC's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. EXAC: 1.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXAC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.41  Med: 6.8 Max: 10.8
Current: 1.41
1.41
10.8
Forward Rate of Return (Yacktman) % -3.89
EXAC's Forward Rate of Return (Yacktman) % is ranked lower than
79% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. EXAC: -3.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EXAC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -4  Med: 8.2 Max: 13.7
Current: -3.89
-4
13.7

More Statistics

Revenue (TTM) (Mil) $262.96
EPS (TTM) $ 0.03
Beta0.44
Short Percentage of Float1.55%
52-Week Range $22.20 - 34.25
Shares Outstanding (Mil)14.35

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 268 287 308 329
EPS ($) 1.30 1.45 1.60 1.75
EPS without NRI ($) 1.30 1.45 1.60 1.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.20%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}